Optimer Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and Canada. It offers DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults; and DIFICID and DIFICLIR tablets for the treatment of Clostridium difficile infection (CDI). The company sells its products to wholesalers and specialty pharmacies. It also has DIFICID under phase 3b(1) clinical trials for the treatment of CDAD prophylaxis in hematopoietic stem cell transplantation patients; under PK trial initiated/phase 3 trial for the treatment of CDAD in pediatric patients; and under phase 3 trial for the treatment of CDAD multiple recurrence. In addition, the company develops Fidaxomicin that is in Phase 1 trial for the treatment of CDI; has Solithromycin product candidate, which completed Phase 2 trials for the treatment of respiratory tract infections; and OPT-822/821 product candidate that is under Phase 2/3 clinical trials for the treatment of metastatic breast cancer. It has collaborative agreements with Astellas Pharma Europe Ltd.; Par Pharmaceuticals, Inc.; Cempra, Inc.; Optimer Biotechnology, Inc.; and Scripps Research Institute. The company was founded in 1998 and is headquartered in Jersey City, New Jersey.

Key Statistics